8-KShareholder Matters

ABBOTT LABORATORIES 8-K Report, Shareholder Vote Results (May 5, 2011)

Filed May 5, 2011For Securities:ABT

Summary

Abbott Laboratories filed an 8-K on May 5, 2011, detailing the results of its Annual Meeting of Shareholders held on April 29, 2011. The primary focus of the filing is the outcome of various shareholder votes on key corporate governance matters. All incumbent directors were overwhelmingly re-elected, indicating strong shareholder confidence in the current board's leadership and strategic direction. Additionally, shareholders ratified the appointment of Deloitte & Touche LLP as the company's independent auditor, a routine but important vote for financial oversight and transparency. The filing also addresses shareholder votes on executive compensation and the frequency of such votes. While shareholders approved the compensation of named executive officers (on an advisory basis), the vote on the frequency of compensation votes indicated a strong preference for annual advisory votes on executive pay. Importantly, a shareholder proposal requesting a price restraint policy on branded pharmaceuticals was overwhelmingly rejected, signaling that shareholders are not currently in favor of such direct price control measures and likely support Abbott's existing pricing strategies.

Key Highlights

  • 1All ten incumbent directors were re-elected with substantial support from shareholders, demonstrating confidence in the existing Board.
  • 2Shareholders ratified the appointment of Deloitte & Touche LLP as Abbott's independent auditor for the upcoming fiscal year.
  • 3An advisory vote on the compensation of named executive officers resulted in approval, with a majority of votes cast in favor.
  • 4Shareholders voted overwhelmingly in favor of holding an advisory vote on executive compensation on an annual basis.
  • 5A shareholder proposal to implement a price restraint policy on branded pharmaceuticals was decisively rejected by a significant margin.

Frequently Asked Questions

The meeting saw the re-election of all directors, ratification of Deloitte & Touche LLP as auditors, approval of executive compensation on an advisory basis, and a strong preference for annual advisory votes on executive pay. A shareholder proposal for pharmaceutical price restraint was rejected.

All ten director nominees were elected with a high percentage of 'Votes For,' significantly outnumbering 'Votes Withheld' and broker non-votes. This indicates broad shareholder support for the current Board.

Shareholders cast a majority of 'Votes For' to approve the compensation of Abbott's named executive officers in an advisory, non-binding vote. Furthermore, shareholders strongly supported holding this advisory vote on executive compensation annually.

No, the shareholder proposal requesting Abbott's Board to create and implement a policy of price restraint on branded pharmaceuticals was overwhelmingly rejected by shareholders, with a vast majority voting against it.